“
“Aim:\n\nGhrelin has been implicated as a modulator of numerous physiological pathways. To date, there have not

been any studies describing the role of ghrelin in modulating the chemoreflex control of pulmonary ventilation. Yet the respiratory system impacts, at least to some degree, on virtually all homeostatic control systems. Chronic hypoxia (CH) can cause fundamental changes in ventilatory control, evident by alterations in the acute hypoxia ventilatory response (HVR). As ghrelin plays an important role in metabolic homeostasis, which is tightly linked to ventilatory control, we hypothesized that ghrelin may modulate HVR, especially following CH.\n\nMethods:\n\nWhole body plethysmography Nocodazole concentration was used to measure the HVR (8% O(2) for 10 min) in male Sprague-Dawley rats (body wt similar to 180-220 g) before and after 14 days of CH (CH = 10% O(2)). During CH, rats received daily subcutaneous injections of either saline (control; n = 5) or ghrelin (150 mu g kg-1 day-1; n = 5). The HVR was measured in another four rats that had received

daily injections of ghrelin during normoxia for 7 days.\n\nResults:\n\nGhrelin did not significantly alter basal ventilatory drive or acute HVR in normoxic rats. However, the acute HVR was accentuated following CH in ghrelin-treated rats compared with saline-treated rats.\n\nConclusions:\n\nThese results describe the impact that ghrelin has in altering ventilatory control following CH and, although the mechanisms remain to be fully elucidated, provide guidance for future ghrelin-based studies interpreting physiological data indirectly www.selleckchem.com/products/Nutlin-3.html related to the chemoreflex control of pulmonary ventilation.”
“Prosthetic valve thrombosis (PVT) is one of the most serious long-term complications after heart valve replacement, and optimal treatment remains unclear. The investigators report clinical

characteristics and outcome of all consecutive patients with PVT treated with urgent surgery or thrombolysis with recombinant tissue plasminogen activator at a single BVD-523 datasheet center from January 1988 to December 2008. Thirty-one patients (mean age 59 years, range 20 to 75, 19% men) were diagnosed with PVT a median of 11 years after valve replacement (range 4 months to 32 years). Affected valve positions were mitral in 17 (55%), aortic in 8 (26%), and tricuspid in 6 (19%), and all but 1 were mechanical valves. Eighteen patients underwent urgent surgery, with 2 deaths in the immediate perioperative phase and 2 recurrences (11%) of PVT over a median follow-up period of 76 months. Of 13 patients treated with thrombolysis, there was immediate clinical improvement after a single administration of recombinant tissue plasminogen activator in 12 (92%), of whom 8 (61%) showed complete response with normalization of echocardiographic findings. The only nonresponder was subsequently referred for urgent surgery.